2018年3月29日 · The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events.

2020年7月28日 · Total metabolic tumor volume (TMTV) is a promising quantitative biomarker for therapy assessment and prognosis in Hodgkin Lymphoma affected patients that allows...

基线肿瘤代谢指标包括最大葡萄糖标准摄取值（SUVmax）、平均摄取值（SUVmean）、总肿瘤代谢体积（TMTV）、总糖酵解率（TLG）。 分析肿瘤代谢参数及临床和血液学相关指标对治疗的影响。 结果 51例患者中，20例复发或进展，中位无进展生存（PFS）期时间为12.0个月（1.0~64.0个月），2年PFS率为25.5%（13/51）。 TMTV、TLG与血清乳酸脱氢酶（LDH）水平的相关性较强。 单因素分析显示Ann Arbor分期、NCCN-IPI评分、TMTV均对预后有显著相关 …

High TMTV at baseline was significantly associated with inferior PFS and OS in patients receiving either lenalidomide maintenance or placebo. Baseline TMTV combined with ECOG PS could improve risk stratification for patients who respond to R-CHOP induction, meeting an unmet need for early and better identification of ultra-risk DLBCL patients.

基线PET对总体代谢肿瘤体积（TMTV）进行检查。 IPET2的结果用Deauville量表标记阴性（DS1- 为更好的 筛查 早期霍奇金 淋巴瘤 （HL）的高危患者，研究人员对基线PET/CT作为总体肿瘤负荷检测方法进行验证。 研究人员筛选 临床 试验H10（NCT00433433）的标准臂里有基线PET和阿霉素、博来霉素、长春花碱和达卡巴嗪治疗两个疗程后的即时PET (iPET2)相关数据的I-II期的HL患者。 基线PET对总体代谢肿瘤体积（TMTV）进行检查。 IPET2的结果用Deauville量表标记阴 …

2022年2月2日 · A total of 258 patients, including 101 classified as early-stage favorable and 157 as early-stage unfavorable disease, had their baseline TMTV calculated by the 41% SUVmax threshold by three different nuclear medicine specialists.

2020年7月23日 · tmtv是r-chop初始治疗有效患者生存结局的有力预后指标，在接受来那度胺维持或安慰剂治疗的患者中，高基线的tmtv与较差pfs和os显着相关。 基线TMTV结合ECOG PS可以改善对R-CHOP诱导有反应的患者的风险分层，满足早期和更好地识别超高风险DLBCL患者的需求。

LyMa-101 试验中纳入的 59 名 MCL 患者的 FDG-PET/CT 已经过独立、盲法和集中审查。 RF 是从摄取最高的疾病区域和总代谢肿瘤体积 (TMTV) 中提取的。 使用两种机器学习模型来比较自体干细胞移植巩固（ASCT）前预测 MRD 的几种组合。 每个算法都是在有或没有临床和实验室参数的约束特征选择的情况下生成的。 与 TMTV 相比，两种算法在摄取率最高的病变中表现出更好的阴性与阳性 MRD 区分性能。 无论机器学习模型如何，临床和生物学特征的有限使用表明 ASCT …

There are two panels that are available in the TMTV workflow mode and we will discuss them in detail below. This panel shows the PT metadata derived from the matched PT displaySet. The user can edit/change the metadata if needed, and by reloading the data the new metadata will be applied to the PT volume.

FDG-PET-based TMTV measurement brings useful, independent, and correlative information to the clinical drug evaluation process. Clario can customize the segmentation threshold settings to meet any special requirements based on disease type or sponsor request or provide measurements based on multiple approaches to segmentation for sponsor ...